Whole blood activated clotting time in infants during extracorporeal membrane oxygenation

T. P. Green, B. Isham-Schopf, Robin H Steinhorn, C. Smith, R. J. Irmiter

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Bleeding complications are the principal cause of morbidity and mortality in infants treated with extracorporeal membrane oxygenation (ECMO). The whole blood activated clotting time (ACT) test is used universally to monitor heparin therapy during this procedure. To enhance our understanding of this test and improve our management of anticoagulation, we studied the relationship between the ACT and blood heparin concentration in nine infants during ECMO. The activated clotting time correlated with the simultaneously determined heparin concentration (r = .55, p < .001 for all patient samples; r = . 92, p < .001 for mean patient values). Within the range of values found in our patients, platelet count, fibrinogen, and fibrin degradation products did not affect the ACT-heparin concentration relationship. However, the interpretation of an individual ACT result was limited by its low precision: the mean difference of duplicate determinations was 9.2%, and the estimation of heparin concentration by a single ACT had a coefficient of variation of 32%. Two commercially available techniques using different activators gave results that differed numerically but correlated well with each other. Both provided similar precision in the estimation of heparin concentration. The ACT is a low cost, bedside test whose accuracy and precision allow the achievement of target heparin concentrations required in infants during ECMO. Multiple determinations, either in duplicate or serially, are needed to achieve satisfactory precision. These data will be useful in designing future studies to determine the optimal serum heparin concentration to provide adequate anticoagulation, but avoid bleeding complications.

Original languageEnglish (US)
Pages (from-to)494-498
Number of pages5
JournalCritical Care Medicine
Volume18
Issue number5
StatePublished - 1990
Externally publishedYes

Fingerprint

Extracorporeal Membrane Oxygenation
Blood Coagulation
Heparin
Hemorrhage
Fibrin Fibrinogen Degradation Products
Infant Mortality
Platelet Count
Morbidity
Costs and Cost Analysis
Serum

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Green, T. P., Isham-Schopf, B., Steinhorn, R. H., Smith, C., & Irmiter, R. J. (1990). Whole blood activated clotting time in infants during extracorporeal membrane oxygenation. Critical Care Medicine, 18(5), 494-498.

Whole blood activated clotting time in infants during extracorporeal membrane oxygenation. / Green, T. P.; Isham-Schopf, B.; Steinhorn, Robin H; Smith, C.; Irmiter, R. J.

In: Critical Care Medicine, Vol. 18, No. 5, 1990, p. 494-498.

Research output: Contribution to journalArticle

Green, TP, Isham-Schopf, B, Steinhorn, RH, Smith, C & Irmiter, RJ 1990, 'Whole blood activated clotting time in infants during extracorporeal membrane oxygenation', Critical Care Medicine, vol. 18, no. 5, pp. 494-498.
Green TP, Isham-Schopf B, Steinhorn RH, Smith C, Irmiter RJ. Whole blood activated clotting time in infants during extracorporeal membrane oxygenation. Critical Care Medicine. 1990;18(5):494-498.
Green, T. P. ; Isham-Schopf, B. ; Steinhorn, Robin H ; Smith, C. ; Irmiter, R. J. / Whole blood activated clotting time in infants during extracorporeal membrane oxygenation. In: Critical Care Medicine. 1990 ; Vol. 18, No. 5. pp. 494-498.
@article{468acb5d80d445dc902b29e130b265e8,
title = "Whole blood activated clotting time in infants during extracorporeal membrane oxygenation",
abstract = "Bleeding complications are the principal cause of morbidity and mortality in infants treated with extracorporeal membrane oxygenation (ECMO). The whole blood activated clotting time (ACT) test is used universally to monitor heparin therapy during this procedure. To enhance our understanding of this test and improve our management of anticoagulation, we studied the relationship between the ACT and blood heparin concentration in nine infants during ECMO. The activated clotting time correlated with the simultaneously determined heparin concentration (r = .55, p < .001 for all patient samples; r = . 92, p < .001 for mean patient values). Within the range of values found in our patients, platelet count, fibrinogen, and fibrin degradation products did not affect the ACT-heparin concentration relationship. However, the interpretation of an individual ACT result was limited by its low precision: the mean difference of duplicate determinations was 9.2{\%}, and the estimation of heparin concentration by a single ACT had a coefficient of variation of 32{\%}. Two commercially available techniques using different activators gave results that differed numerically but correlated well with each other. Both provided similar precision in the estimation of heparin concentration. The ACT is a low cost, bedside test whose accuracy and precision allow the achievement of target heparin concentrations required in infants during ECMO. Multiple determinations, either in duplicate or serially, are needed to achieve satisfactory precision. These data will be useful in designing future studies to determine the optimal serum heparin concentration to provide adequate anticoagulation, but avoid bleeding complications.",
author = "Green, {T. P.} and B. Isham-Schopf and Steinhorn, {Robin H} and C. Smith and Irmiter, {R. J.}",
year = "1990",
language = "English (US)",
volume = "18",
pages = "494--498",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Whole blood activated clotting time in infants during extracorporeal membrane oxygenation

AU - Green, T. P.

AU - Isham-Schopf, B.

AU - Steinhorn, Robin H

AU - Smith, C.

AU - Irmiter, R. J.

PY - 1990

Y1 - 1990

N2 - Bleeding complications are the principal cause of morbidity and mortality in infants treated with extracorporeal membrane oxygenation (ECMO). The whole blood activated clotting time (ACT) test is used universally to monitor heparin therapy during this procedure. To enhance our understanding of this test and improve our management of anticoagulation, we studied the relationship between the ACT and blood heparin concentration in nine infants during ECMO. The activated clotting time correlated with the simultaneously determined heparin concentration (r = .55, p < .001 for all patient samples; r = . 92, p < .001 for mean patient values). Within the range of values found in our patients, platelet count, fibrinogen, and fibrin degradation products did not affect the ACT-heparin concentration relationship. However, the interpretation of an individual ACT result was limited by its low precision: the mean difference of duplicate determinations was 9.2%, and the estimation of heparin concentration by a single ACT had a coefficient of variation of 32%. Two commercially available techniques using different activators gave results that differed numerically but correlated well with each other. Both provided similar precision in the estimation of heparin concentration. The ACT is a low cost, bedside test whose accuracy and precision allow the achievement of target heparin concentrations required in infants during ECMO. Multiple determinations, either in duplicate or serially, are needed to achieve satisfactory precision. These data will be useful in designing future studies to determine the optimal serum heparin concentration to provide adequate anticoagulation, but avoid bleeding complications.

AB - Bleeding complications are the principal cause of morbidity and mortality in infants treated with extracorporeal membrane oxygenation (ECMO). The whole blood activated clotting time (ACT) test is used universally to monitor heparin therapy during this procedure. To enhance our understanding of this test and improve our management of anticoagulation, we studied the relationship between the ACT and blood heparin concentration in nine infants during ECMO. The activated clotting time correlated with the simultaneously determined heparin concentration (r = .55, p < .001 for all patient samples; r = . 92, p < .001 for mean patient values). Within the range of values found in our patients, platelet count, fibrinogen, and fibrin degradation products did not affect the ACT-heparin concentration relationship. However, the interpretation of an individual ACT result was limited by its low precision: the mean difference of duplicate determinations was 9.2%, and the estimation of heparin concentration by a single ACT had a coefficient of variation of 32%. Two commercially available techniques using different activators gave results that differed numerically but correlated well with each other. Both provided similar precision in the estimation of heparin concentration. The ACT is a low cost, bedside test whose accuracy and precision allow the achievement of target heparin concentrations required in infants during ECMO. Multiple determinations, either in duplicate or serially, are needed to achieve satisfactory precision. These data will be useful in designing future studies to determine the optimal serum heparin concentration to provide adequate anticoagulation, but avoid bleeding complications.

UR - http://www.scopus.com/inward/record.url?scp=0025285537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025285537&partnerID=8YFLogxK

M3 - Article

C2 - 2328593

AN - SCOPUS:0025285537

VL - 18

SP - 494

EP - 498

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 5

ER -